Hemovigilance is the systematic surveillance of adverse events and reactions across the entire transfusion chain — from blood donation and component processing through storage, distribution, and ultimately transfusion into a patient — with the goal of detecting, reporting, investigating, and preventing transfusion-related harm. The term originated in France in the early 1990s (hémovigilance) and has since been adopted internationally as the standard word for organized transfusion-safety surveillance, including by the World Health Organization and national programs such as the UK’s Serious Hazards of Transfusion (SHOT) scheme and the United States’ CDC National Healthcare Safety Network (NHSN) Hemovigilance Module.
For a US transfusion service, blood bank, or hospital laboratory, hemovigilance is not an abstract concept — it is the practical infrastructure of recognizing a transfusion reaction, classifying it using standardized definitions, reporting it (internally and, where applicable, to CDC NHSN), and feeding that data back into corrective action. This guide covers what hemovigilance means operationally, how the CDC NHSN Hemovigilance Module works, how hemovigilance differs from the broader term biovigilance, and what a working hemovigilance program looks like in practice.
Hemovigilance Definition: What Counts as Hemovigilance Activity
Operationally, an activity or system is hemovigilance when it does all of the following:
- It captures adverse events or reactions tied to a specific unit or component of donated blood — not general lab safety incidents unrelated to transfusion.
- It uses standardized case definitions (in the US, largely aligned with definitions developed by the International Society of Blood Transfusion (ISBT) Working Party on Haemovigilance) so that reactions of the same type are classified consistently across institutions.
- It follows a defined reporting pathway — from the bedside or point of transfusion, to the transfusion service or blood bank, and in many cases onward to a national or regional surveillance system.
- It closes the loop: the data collected is used for trending, root-cause investigation, and process or product changes, not simply archived.
A single nurse documenting “patient felt warm during transfusion” in a chart is not, by itself, hemovigilance. A transfusion service that receives that report, classifies it against a standard reaction category (e.g., febrile non-hemolytic transfusion reaction), logs it, and reports aggregate data to a surveillance system is running a hemovigilance program.
The CDC NHSN Hemovigilance Module
In the United States, the primary national reporting infrastructure for transfusion-related adverse events is the CDC National Healthcare Safety Network (NHSN) Hemovigilance Module (the module was previously known as the Biovigilance Component of NHSN before being restructured). NHSN is the CDC’s healthcare-associated infection and adverse-event tracking system, and the Hemovigilance Module is the part of it built specifically for transfusion services.
Facilities that enroll report structured data on:
- Transfusion reactions — classified using standardized definitions covering categories such as febrile non-hemolytic transfusion reaction (FNHTR), allergic and anaphylactic reactions, acute and delayed hemolytic transfusion reactions, transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), transfusion-associated dyspnea, and transfusion-transmitted infection.
- Incidents — errors or deviations in the transfusion process (such as a mislabeled sample or a component issued to the wrong patient) that were caught before, or occurred without, causing patient harm.
- Denominator data — total units transfused by component type, which lets a facility calculate its own reaction rates and benchmark against national aggregate data CDC publishes back to participants.
Enrollment in the NHSN Hemovigilance Module is voluntary at the federal level, but many transfusion services participate because it directly supports obligations they already carry under accreditation and quality-system standards — including AABB Standards for Blood Banks and Transfusion Services (which require a documented adverse-event reporting and investigation process), Joint Commission transfusion-related requirements, and College of American Pathologists (CAP) Laboratory Accreditation Program checklist items on transfusion reaction workup and reporting. Participating separately from NHSN, blood collection establishments (as opposed to transfusion services) have their own FDA reporting obligation: fatalities related to blood collection or transfusion must be reported to the FDA under 21 CFR 606.170.
Hemovigilance vs. Biovigilance
The two terms are related but not identical, and mixing them up is a common source of confusion when searching CDC or AABB material:
- Hemovigilance is scoped specifically to whole blood and blood components — red cells, platelets, plasma, cryoprecipitate, and the transfusion process itself.
- Biovigilance is the broader umbrella term, covering blood and blood components plus other biologics such as tissues, cellular therapies, and organs. CDC’s program in this space was originally named the “Biovigilance Component” of NHSN before the transfusion-focused portion was renamed the Hemovigilance Module; AABB has historically used “biovigilance” to describe its wider patient-safety surveillance work across the full range of biological products, not blood alone.
In practice, if the content you’re looking for is specifically about transfusion reactions and blood component safety, “hemovigilance” and “CDC NHSN Hemovigilance Module” are the more precise search terms. “Biovigilance” is the right term when tissue or cellular-therapy surveillance is also in scope.
Transfusion Reactions Tracked Under Hemovigilance Surveillance
A working hemovigilance program needs shared definitions for what it is counting. The reaction categories most consistently tracked across CDC NHSN and international hemovigilance systems include:
- Febrile non-hemolytic transfusion reaction (FNHTR) — fever and/or chills during or shortly after transfusion without hemolysis.
- Allergic reaction / anaphylaxis — ranging from mild urticaria to severe anaphylactic reactions to plasma proteins in the transfused component.
- Acute hemolytic transfusion reaction (AHTR) — typically ABO-incompatibility driven, and one of the most serious preventable transfusion errors.
- Delayed hemolytic / delayed serologic transfusion reaction — hemolysis or a new alloantibody detected days to weeks after transfusion.
- Transfusion-associated circulatory overload (TACO) — volume-overload pulmonary edema, now recognized as one of the leading causes of transfusion-related fatality.
- Transfusion-related acute lung injury (TRALI) — acute lung injury temporally associated with transfusion, historically linked to donor antibodies.
- Transfusion-transmitted infection (TTI) — bacterial, viral, or other pathogen transmission traced to a transfused component.
Consistent use of these categories — rather than free-text description — is what allows a hospital’s data to be aggregated meaningfully into national hemovigilance statistics, and it is what CDC NHSN’s structured reporting fields are built around.
Building a Hemovigilance Reporting Program
For a transfusion service or hospital blood bank setting up or maturing a hemovigilance program, the core components are:
- A clear reaction-reporting pathway. Nursing and bedside staff need an unambiguous, low-friction way to flag a suspected reaction the moment it’s recognized, including who to notify and what immediate steps to take (stopping the transfusion, maintaining IV access, returning the unit and tubing to the blood bank).
- Standardized workup and classification. The transfusion service confirms clerical accuracy, performs the required serologic workup, and classifies the event against standard definitions rather than an ad hoc description.
- Internal trending. Reaction rates should be tracked over time and by component type/supplier so an increase in a specific reaction category triggers investigation rather than going unnoticed in individual case files.
- External reporting. Where applicable, data flows to CDC NHSN’s Hemovigilance Module, and fatalities tied to blood collection or transfusion are reported to FDA under 21 CFR 606.170. Some states also run their own hemovigilance or adverse-event reporting requirements layered on top of federal ones.
- Feedback and corrective action. Findings get reviewed by a transfusion committee or equivalent quality body, with corrective actions tracked to closure — the step that turns surveillance data into an actual reduction in patient harm.
This same reporting-classification-feedback structure is what most vendor and supplier quality programs are built around more broadly — see CASRAI’s guide to quality agreements for how responsibility for this kind of deviation and adverse-event handling gets formally allocated when a supplier or contract facility is involved.
Hemovigilance Outside the US
Hemovigilance as an organized discipline predates the CDC NHSN module by roughly two decades. France established the first formal national hemovigilance system in the early 1990s, and the World Health Organization has since promoted hemovigilance as a component of national blood safety strategy globally. The UK’s Serious Hazards of Transfusion (SHOT) scheme, running since the mid-1990s, is one of the longest-continuously-operating national hemovigilance programs and is frequently cited as a model for the reaction-classification and reporting-culture approach that later US systems, including CDC NHSN, have drawn on.
Frequently Asked Questions
What is hemovigilance?
Hemovigilance is the organized surveillance of adverse events and reactions across the transfusion chain, from blood donation through transfusion, used to detect, report, investigate, and prevent transfusion-related harm.
What is CDC hemovigilance / the CDC NHSN Hemovigilance Module?
It is the transfusion-safety-focused reporting module within CDC’s National Healthcare Safety Network (NHSN), through which US transfusion services can report transfusion reactions, transfusion-related incidents, and units-transfused denominator data, supporting national surveillance of transfusion safety.
Is NHSN hemovigilance reporting mandatory?
Enrollment in the NHSN Hemovigilance Module itself is voluntary at the federal level, though many transfusion services participate because it helps satisfy adverse-event reporting expectations under AABB Standards, Joint Commission requirements, and CAP accreditation checklists. Separately, blood collection establishments must report transfusion- or collection-related fatalities to FDA under 21 CFR 606.170.
What is the difference between hemovigilance and biovigilance?
Hemovigilance covers whole blood and blood components specifically. Biovigilance is the broader term that also covers tissues, cellular therapies, and other biologics; CDC’s transfusion-focused reporting was originally named the Biovigilance Component before being renamed the Hemovigilance Module.
What counts as a hemovigilance transfusion reaction?
Standard categories tracked under hemovigilance systems include febrile non-hemolytic transfusion reaction, allergic/anaphylactic reaction, acute and delayed hemolytic transfusion reaction, TACO, TRALI, and transfusion-transmitted infection.
